Basilea Pharmaceutica AG Stock
Stocks
BSLN
CH0011432447
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Swiss Exchange
11:30:53 2026-09-25 EDT
|
5-day change | 1st Jan Change | ||
| 68.70 CHF | -0.58% |
|
-0.43% | +25.59% |
| 09-14 | Japanese Stocks Fall on AI Development Slowdown Calls; Oil Gains | MT |
| 09-14 | Asahi Kasei Unit Starts Phase Two Study of Antifungal Cresemba for Pediatric Patients in Japan | MT |
| Market Cap | 853M 1.03B 903M 777M 1.46B 98.66B 1.47B 10.21B 3.95B 50.41B 3.87B 3.78B 162B | P/E 2026 * |
16x | P/E 2027 * | 17.8x |
|---|---|---|---|---|---|
| Enterprise Value | 700M 845M 742M 638M 1.19B 81B 1.2B 8.38B 3.25B 41.38B 3.17B 3.1B 133B | EV / Sales 2026 * |
2.61x | EV / Sales 2027 * | 2.31x |
| Free-Float |
91.74% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Swiss Exchange
| BSLN | Delayed | |
CBOE
| 0QNA | Real-time | |
|
London S.E.
| 0QNA | Delayed | |
|
OTC Markets
| BPMUF | Delayed | |
|
Tradegate
| PK5 | Real-time | |
|
Deutsche Boerse AG
| PK5 | Delayed | |
|
Börse Stuttgart
| PK5 | Delayed | |
|
Boerse Muenchen
| PK5 | Real-time |
Last Transcript: Basilea Pharmaceutica AG
| 1 day | -0.58% | ||
| 1 week | -0.43% | ||
| Current month | +8.19% | ||
| 1 month | +5.21% | ||
| 3 months | +31.61% | ||
| 6 months | +32.88% | ||
| Current year | +25.59% |
| 1 week | 67.4 |  | 70.5 |
| 1 month | 62.2 | | 70.5 |
| Current year | 47.8 | | 70.5 |
| 1 year | 44.7 | | 70.5 |
| 3 years | 32 | | 70.5 |
| 5 years | 29.55 | | 70.5 |
| 10 years | 29.28 | | 95.35 |
| Manager | Title | Age | Since |
|---|---|---|---|
David Veitch
CEO | Chief Executive Officer | 61 | 2018-04-18 |
Adesh Kaul
DFI | Director of Finance/CFO | 52 | 2019-04-09 |
Gerrit Hauck
CTO | Chief Tech/Sci/R&D Officer | 62 | 2018-04-30 |
| Director | Title | Age | Since |
|---|---|---|---|
Thomas Werner
BRD | Director/Board Member | 70 | 2011-11-28 |
| Chairman | 71 | 2013-04-08 | |
Nicole Onetto
BRD | Director/Board Member | 73 | 2017-04-26 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 5/29/26 | Sell | -400 | 0.0030% | |||
| 5/13/26 | Sell | -1,043 | 0.0078% | |||
| 5/4/26 | Sell | 400 | 0.0030% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.58% | -0.43% | +49.19% | +62.60% | 1.03B | |
| -0.14% | +4.33% | +9.88% | +31.73% | 47.97B | |
| -1.69% | +1.48% | +53.02% | +33.59% | 44.5B | |
| +2.56% | +7.34% | +382.17% | +594.81% | 43.93B | |
| +0.24% | +2.85% | +9.78% | +89.54% | 41.03B | |
| -0.62% | -1.11% | +4.70% | +46.02% | 29.85B | |
| -0.28% | +1.07% | +26.83% | +152.91% | 17.27B | |
| -0.46% | +1.20% | +26.78% | +41.32% | 15.3B | |
| -2.21% | -4.70% | - | - | 14.82B | |
| +3.37% | +9.21% | +9.93% | - | 15.34B | |
| Average | +0.02% | +2.07% | +63.59% | +131.57% | 27.1B | |
| Weighted average by Cap. | +0.10% | +2.85% | +82.90% | +155.81% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 268M 323M 284M 244M 457M 30.99B 460M 3.21B 1.24B 15.83B 1.21B 1.19B 50.88B | 275M 332M 291M 251M 469M 31.82B 473M 3.29B 1.28B 16.26B 1.25B 1.22B 52.25B |
| Net income | 68.7M 82.89M 72.74M 62.6M 117M 7.94B 118M 822M 318M 4.06B 311M 304M 13.04B | 58.3M 70.35M 61.73M 53.13M 99.46M 6.74B 100M 698M 270M 3.44B 264M 258M 11.07B |
| Net Debt | -153M -184M -162M -139M -260M -17.66B -262M -1.83B -708M -9.02B -692M -677M -28.99B | -218M -263M -231M -199M -372M -25.2B -374M -2.61B -1.01B -12.87B -987M -966M -41.37B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-09-25 | CHF 68.70 | -0.58% | 17,433 |
| 26-09-24 | CHF 69.10 | -0.43% | 22,513 |
| 26-09-23 | CHF 69.40 | +1.17% | 27,440 |
| 26-09-22 | CHF 68.60 | -0.58% | 46,487 |
| 26-09-21 | CHF 69.00 | 0.00% | 35,900 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- BSLN Stock
Select your edition
All financial news and data tailored to specific country editions
